Mineralys Therapeutics Announces Pricing of $175.0 Million Underwritten Public Offering of Common Stock

Core Viewpoint - Mineralys Therapeutics, Inc. has announced a public offering of 12,962,962 shares at a price of $13.50 per share, aiming to raise approximately$175.0 million before expenses [1][3]. Group 1: Offering Details - The public offering is expected to close on or about March 13, 2025, pending customary closing conditions [1]. - The underwriters have a 30-day option to purchase an additional 1,944,444 shares [1]. - The offering is being managed by BofA Securities, Evercore ISI, Goldman Sachs & Co. LLC, Stifel, and Wells Fargo Securities as joint book-running managers [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be used to fund the clinical development of lorundrostat, including research, development, manufacturing, and pre-commercialization activities, as well as for working capital and general corporate purposes [3]. Group 3: Company Overview - Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA), and other diseases related to dysregulated aldosterone [6]. - The company's lead product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor targeting cardiorenal conditions [6].